Compare Bumble Inc (BMBL) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bumble Inc vs Crispr Therapeutics AG — how do they compare? Bumble Inc trades at $2.99 (market cap $382.16M), while Crispr Therapeutics AG trades at $50.51 (market cap $4.97B). The key difference: Crispr Therapeutics AG is far larger — about 13× Bumble Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.
| BMBL | CRSP | |
|---|---|---|
Market Cap | $382.16M | $4.97B |
Sector | Technology | Health |
52-Week High | $8.57 | $76.78 |
52-Week Low | $2.70 | $44.34 |
Enterprise Value | $733.84M | $3.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMBL trades at $3.11, up 2.64% over 24 hours, with a neutral technical signal and bearish moving averages. The company reported a Q1 2026 EPS beat but faces declining revenue and a net loss of -$693.14M for 2025. Recent news highlights a potential sale exploration and an AI-driven product overhaul to counter slowing growth and payer declines.
Outlook remains speculative with a consensus price target of $4.37, offering 40% upside, but risks include persistent losses, high debt, and intense competition. Execution of the strategic reset is critical for a turnaround, with cash flow improvements providing a slight cushion amid operational challenges.
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bumble Inc
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
